EFS and lung carcinoma: Studies with pendimethalin also indicate diverse results; cell viability was decreased in human umbilical vein endothelial cells, HUVECs, treated with 50 and 100 μM pendimethalin, and the proportion of apoptotic and necrotic cells was increased [35], but on the other hand, the effects of pendimethalin in A549 human lung carcinoma cells after 24 h’ exposure with 100 μM altered the apoptosis-related gene expression and significantly downregulated BAX, P53, and CAS3, suppressing apoptosis and allowing cancer cells to grow and proliferate [36].